Amylyx’s ALS Drug Fails in Late-Stage Study

Published on March 8, 2024

Amylyx Pharmaceuticals said on Friday its approved treatment for a neurological disorder called amyotrophic lateral sclerosis failed in a late-stage trial, sending its shares crashing 75% before the bell. The U.S. Food and Drug Administration approved the drug, branded as…

Read Full Article (External Site)